|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...4849505152535455565758...156157» |
- Trial completion, Enrollment change, Trial primary completion date: Pacing Activity Self-management for Patients With Multiple Sclerosis (clinicaltrials.gov) - Dec 17, 2015
P2, N=31, Completed, Sponsor: Vrije Universiteit Brussel
Recruiting --> Completed | N=50 --> 31 | Trial primary completion date: Feb 2013 --> Feb 2014
- ||| Orencia (abatacept) / BMS
New trial: Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=400, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Xeljanz (tofacitinib) / Pfizer
Clinical: Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Dec 17, 2015
P4, N=25, Not yet recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Completed | N=50 --> 31 | Trial primary completion date: Feb 2013 --> Feb 2014 Initiation date: Feb 2015 --> Jan 2016
- ZB-168 / Zura Bio
Enrollment change, Trial primary completion date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Dec 17, 2015
P1, N=4, Terminated, Sponsor: Pfizer
Initiation date: Feb 2015 --> Jan 2016 N=60 --> 4 | Trial primary completion date: Jan 2016 --> Oct 2015
- Trial completion, Phase classification, Enrollment change, Trial primary completion date, Surgery: BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis) (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=212, Completed, Sponsor: S. Anna Hospital
N=60 --> 4 | Trial primary completion date: Jan 2016 --> Oct 2015 Recruiting --> Completed | Phase classification: P3 --> PN/A | N=679 --> 212 | Trial primary completion date: Dec 2015 --> Dec 2014
- Trial primary completion date: Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Lahey Clinic
Recruiting --> Completed | Phase classification: P3 --> PN/A | N=679 --> 212 | Trial primary completion date: Dec 2015 --> Dec 2014 Trial primary completion date: Sep 2015 --> Dec 2016
- elezanumab (ABT-555) / AbbVie
Trial suspension: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Dec 16, 2015
P1, N=20, Suspended, Sponsor: AbbVie
Trial primary completion date: Sep 2015 --> Dec 2016 Recruiting --> Suspended
- New trial: Insulin-based Strategies to Prevent Hypoglycemia During Exercise (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=23, Not yet recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
- New trial: Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=46, Completed, Sponsor: Yaounde Central Hospital
- New trial: Young With Diabetes Type 1 - Test of an mHealth App (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=140, Recruiting, Sponsor: Nordsjaellands Hospital
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Trial primary completion date: BEER: How to be Safe With Alcoholic Drinks in Diabetes (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=24, Recruiting, Sponsor: Kinderkrankenhaus auf der Bult
Recruiting --> Suspended Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Apr 2016
- | Enrollment closed, Enrollment change: An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement (clinicaltrials.gov) - Dec 16, 2015
P4, N=42, Active, not recruiting, Sponsor: DePuy International
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Apr 2016 Recruiting --> Active, not recruiting | N=300 --> 42
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion, Trial primary completion date: REASSURE2: Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. (clinicaltrials.gov) - Dec 16, 2015
P3, N=241, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=300 --> 42 Recruiting --> Completed | Trial primary completion date: Jan 2020 --> May 2015
- New trial: Walk SLE: Walk With Ease Program For Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=50, Not yet recruiting, Sponsor: University of North Carolina, Chapel Hill
- Enrollment closed, Trial primary completion date: Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms (clinicaltrials.gov) - Dec 15, 2015
P2, N=30, Active, not recruiting, Sponsor: In Home Closed Loop Study Group
Recruiting --> Completed | Trial primary completion date: Jan 2020 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Feb 2016
- Trial completion, Trial primary completion date: The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients (clinicaltrials.gov) - Dec 14, 2015
P=N/A, N=6, Completed, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Feb 2016 Not yet recruiting --> Completed | Trial primary completion date: Apr 2014 --> Sep 2015
- |||||| Lupuzor (rigerimod) / ImmuPharma, Alora Pharma
Enrollment open, Trial initiation date: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Dec 14, 2015
P3, N=200, Recruiting, Sponsor: ImmuPharma
Not yet recruiting --> Completed | Trial primary completion date: Apr 2014 --> Sep 2015 Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Dec 2015
- ||| sovleplenib (HMPL-523) / Hutchmed
Trial completion, Enrollment change: A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 (clinicaltrials.gov) - Dec 14, 2015
P1, N=118, Completed, Sponsor: Hutchison Medipharma Limited
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Dec 2015 Recruiting --> Completed | N=72 --> 118
- ||||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Trial completion, Enrollment change: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Dec 14, 2015
P3, N=730, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=72 --> 118 Active, not recruiting --> Completed | N=500 --> 730
- New trial: HYKRAND: Studies on the Adaptive Responses to Hypoxia (clinicaltrials.gov) - Dec 14, 2015
P=N/A, N=30, Recruiting, Sponsor: Karolinska University Hospital
- Enrollment open, IO biomarker: Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=20, Recruiting, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed | N=500 --> 730 Active, not recruiting --> Recruiting
- leucovorin calcium / Generic mfg.
Enrollment change: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Dec 12, 2015
P2, N=99, Terminated, Sponsor: University of Arkansas
Active, not recruiting --> Recruiting N=160 --> 99
- ||| Humira (adalimumab) / AbbVie
New trial, Real-world evidence, Real-world: ROCKA: Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab (clinicaltrials.gov) - Dec 11, 2015
P=N/A, N=100, Recruiting, Sponsor: AbbVie
- New P2 trial: Diabeloop WP6.2 : Crossover Evaluation of Glycemic Control (clinicaltrials.gov) - Dec 11, 2015
P2, N=36, Recruiting, Sponsor: Centre d
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P4 trial: RENTGPA: Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis (clinicaltrials.gov) - Dec 11, 2015
P4, N=28, Not yet recruiting, Sponsor: Hospital for Special Surgery, New York
- New P2 trial: Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation (clinicaltrials.gov) - Dec 10, 2015
P2, N=12, Not yet recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
- ||| New P1 trial: A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen (clinicaltrials.gov) - Dec 10, 2015
P1, N=160, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Enrollment open: RISPENDO: the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia (clinicaltrials.gov) - Dec 10, 2015
P0, N=30, Recruiting, Sponsor: Radboud University
N=160 --> 99 Not yet recruiting --> Recruiting
- Admelog (insulin lispro biosimilar) / Sanofi
Enrollment open: Assessment of the Safety of SAR342434 and Humalog (clinicaltrials.gov) - Dec 10, 2015
P1, N=24, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Nerventra (laquinimod) / Active Biotech
Trial primary completion date: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease (clinicaltrials.gov) - Dec 10, 2015
P2, N=211, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
Not yet recruiting --> Recruiting Trial primary completion date: May 2014 --> Dec 2023
- || Enrollment closed, Trial primary completion date: PRISM: Pictorial Representation of Illness and Self Measure (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=220, Active, not recruiting, Sponsor: University of Oxford
Trial primary completion date: May 2014 --> Dec 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016
- Trial primary completion date: WIRMS: Worms for Immune Regulation of Multiple Sclerosis (clinicaltrials.gov) - Dec 10, 2015
P2, N=72, Recruiting, Sponsor: University of Nottingham
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016 Trial primary completion date: Nov 2014 --> Mar 2016
- New trial: ficolupus: Anti-ficolin-3 Autoantibodies in Lupus Nephritis (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=213, Completed, Sponsor: University Hospital, Grenoble
- ||| SAR438544 / Sanofi
New P1 trial: A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients (clinicaltrials.gov) - Dec 10, 2015
P1, N=70, Not yet recruiting, Sponsor: Sanofi
- |||| dimethyl fumarate / Generic mfg.
Enrollment open: DIMAT-MS: Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 10, 2015
P4, N=75, Recruiting, Sponsor: University Hospital Muenster
Trial primary completion date: Nov 2014 --> Mar 2016 Not yet recruiting --> Recruiting
- || Enrollment closed, Trial primary completion date, HEOR: INCONTROL: The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=52, Active, not recruiting, Sponsor: VU University Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Apr 2016
- | RSLV-132 / Resolve
Trial completion, Phase classification: Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Dec 10, 2015
P1, N=32, Completed, Sponsor: Resolve Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Apr 2016 Active, not recruiting --> Completed | Phase classification: P2 --> P1
- ||| Rebif (human IFN-?-1a) / EMD Serono
Enrollment closed, Trial primary completion date: PROCEED: Effectiveness of Rebif (clinicaltrials.gov) - Dec 9, 2015
P4, N=106, Active, not recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed | Phase classification: P2 --> P1 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Aug 2016
- | Trial completion, Trial primary completion date: CGM-Teens: Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control (clinicaltrials.gov) - Dec 7, 2015
P3, N=121, Completed, Sponsor: Nemours Children's Clinic
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Aug 2016 Recruiting --> Completed | Trial primary completion date: Nov 2013 --> Nov 2015
- || Orencia (abatacept) / BMS
Enrollment closed: Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL (clinicaltrials.gov) - Dec 7, 2015
P=N/A, N=370, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | Trial primary completion date: Nov 2013 --> Nov 2015 Recruiting --> Active, not recruiting
- || Enrollment closed, Trial primary completion date: IMAGINE-RA: An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: Professor of Rheumatology, MD, DMSci, Kim Horslev-Petersen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Jun 2017
- ||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Dec 6, 2015
P3, N=596, Completed, Sponsor: Samsung Bioepis Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Apr 2014
- Biomarker, Enrollment status: Salivary Biomarkers for Sj (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=420, Enrolling by invitation, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Apr 2014 Recruiting --> Enrolling by invitation
- Trial completion, Trial primary completion date: Educational Efficacy Assessment of a Serious Game to Teach Insulin Therapy to Primary Care Physicians (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=170, Completed, Sponsor: Universidade Estadual de Londrina
Recruiting --> Enrolling by invitation Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Dec 2015
- || Betaseron (IFN-β-1b) / Bayer
Trial primary completion date, Adherence: BETAEVAL: BAY86-5046 (Betaseron), Non Interventional Studies (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=150, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Sep 2015 --> Mar 2016
- || dimethyl fumarate / Generic mfg.
Trial primary completion date: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - Dec 6, 2015
P2, N=70, Recruiting, Sponsor: Biogen
Trial primary completion date: Sep 2015 --> Mar 2016 Trial primary completion date: Nov 2015 --> Jul 2016
- Trial primary completion date: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=40, Recruiting, Sponsor: University of Rochester
Trial primary completion date: Nov 2015 --> Jul 2016 Trial primary completion date: Apr 2016 --> Dec 2016
- Enrollment closed, Trial primary completion date: Upper Limbs Intervention in Multiple Sclerosis (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Universidad de Granada
Trial primary completion date: Apr 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Aug 2015
- ||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Trial completion: A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Dec 6, 2015
P3, N=544, Completed, Sponsor: Samsung Bioepis Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Aug 2015 Active, not recruiting --> Completed
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: Depression and Anxiety in Rheumatoid Arthritis (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: University of Pavia
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Dec 2015